"The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
Multiple myeloma is a form of blood cancer that p"...
- Clinician Information:
AdreView Patient Information including How Should I Take
In this Article
- What is iobenguane I-123 (AdreView)?
- What are the possible side effects of iobenguane I-123 (AdreView)?
- What is the most important information I should know about iobenguane I-123 (AdreView)?
- What should I discuss with my health care provider before receiving iobenguane I-123 (AdreView)?
- How is iobenguane I-123 given (AdreView)?
- What happens if I miss a dose (AdreView)?
- What happens if I overdose (AdreView)?
- What should I avoid while receiving iobenguane I-123 (AdreView)?
- What other drugs will affect iobenguane I-123 (AdreView)?
- Where can I get more information?
What should I discuss with my health care provider before receiving iobenguane I-123 (AdreView)?
You should not receive this medication if you are allergic to iobenguane. Tell your doctor if you have ever had any type of reaction to another contrast agent, or to potassium.
To make sure you can safely receive iobenguane I-123, tell your doctor if you have any of these other conditions:
- kidney disease;
- a thyroid disorder;
- if you are dehydrated or unable to urinate; or
- if you are allergic to iodine.
FDA pregnancy category C. It is not known whether iobenguane I-123 will harm an unborn baby. Tell your doctor if you are pregnant before you are treated with iobenguane I-123.
It is not known whether iobenguane I-123 passes into breast milk or if it could harm a nursing baby. Do not breast-feed within 6 days after receiving iobenguane I-123. If you use a breast pump during this time, throw out any milk you collect. Do not feed it to your baby.
Older adults may need kidney function tests before receiving iobenguane I-123. Your kidney function may also need to be watched closely after you have received this medication.
How is iobenguane I-123 given (AdreView)?
Iobenguane I-123 is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. It is usually given about 24 hours before your radiologic test.
At least 1 hour before you are treated with iobenguane I-123, you will be given a liquid drink that contains medicine to protect your thyroid from harmful radioactive effects of iobenguane I-123.
Drink extra fluids before you receive iobenguane I-123, and for at least 48 hours afterward. Follow your doctor's instructions about the types and amount of liquids you should drink before and after your test. Iobenguane I-123 is radioactive and it can cause dangerous effects on your bladder if it is not properly eliminated from your body through urination.
Expect to urinate often during the first 48 hours after your test. You will know you are getting enough extra fluid if you are urinating more than usual during this time. Urinating often will help rid your body of the radioactive iodine.
Additional AdreView Information
- AdreView Drug Interactions Center: iobenguane sulfate i-123 iv
- AdreView Side Effects Center
- AdreView FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.